Latest Articles
Lactate-Induced M2 Macrophages Boost Endometrial Cancer Progression - BIOENGINEER.ORG
Lactate-Induced M2 Macrophages Boost Endometrial Cancer Progression BIOENGINEER.ORG
Published: Aug. 29, 2025, 10:40 p.m.
Host Lola Weippert: Forced Break Due to Meningitis - MSN
Host Lola Weippert: Forced Break Due to Meningitis MSN
Published: Aug. 28, 2025, 10:49 p.m.
Advanced analytics toolkit walkthrough for QCR Holdings Inc. - Market Weekly Review & Low Volatility Stock Suggestions - Newser
Advanced analytics toolkit walkthrough for QCR Holdings Inc. - Market Weekly Review & Low Volatility Stock Suggestions Newser
Published: Aug. 28, 2025, 1:01 p.m.
Erastin-Induced Multi-Pathway Cell Death in Endometriosis: A Mechanistic and Translational Narrative Review - Frontiers
Erastin-Induced Multi-Pathway Cell Death in Endometriosis: A Mechanistic and Translational Narrative Review Frontiers
Published: Aug. 27, 2025, 8:39 p.m.
Advanced Fellowship in Minimally Invasive Gynecological Surgery (AF MIGS) - VA.gov Home | Veterans Affairs
Advanced Fellowship in Minimally Invasive Gynecological Surgery (AF MIGS) VA.gov Home | Veterans Affairs
Published: Aug. 26, 2025, 9:45 p.m.
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced - PharmiWeb.com
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced PharmiWeb.com
Published: Aug. 26, 2025, 4:10 p.m.
Rina-S Earns Breakthrough Designation in Advanced Endometrial Cancer - Curetoday
Rina-S Earns Breakthrough Designation in Advanced Endometrial Cancer Curetoday
Published: Aug. 26, 2025, 4:06 p.m.
Olaparib Maintenance in Advanced Endometrial Cancer Trial - BIOENGINEER.ORG
Olaparib Maintenance in Advanced Endometrial Cancer Trial BIOENGINEER.ORG
Published: Aug. 26, 2025, 3:07 p.m.
Rina-S Wins FDA Breakthrough Therapy Designation for Advanced or Recurrent Endometrial Cancer - OncLive
Rina-S Wins FDA Breakthrough Therapy Designation for Advanced or Recurrent Endometrial Cancer OncLive
Published: Aug. 26, 2025, 3:01 p.m.
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) - Yahoo Finance
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) Yahoo Finance
Published: Aug. 26, 2025, noon
Link copied to clipboard!